Literature DB >> 15557619

Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung.

Ciara M Shaver1, Alan R Hauser.   

Abstract

Pseudomonas aeruginosa uses a type III secretion system to promote development of severe disease, particularly in patients with impaired immune defenses. While the biochemical and enzymatic functions of ExoU, ExoS, and ExoT, three effector proteins secreted by this system, are well defined, the relative roles of each protein in the pathogenesis of acute infections is not clearly understood. Since ExoU and ExoS are usually not secreted by the same strain, it has been difficult to directly compare the effects of these proteins during infection. In the work described here, several isogenic mutants of a bacterial strain that naturally secretes ExoU, ExoS, and ExoT were generated to carefully evaluate the relative contribution of each effector protein to pathogenesis in a mouse model of acute pneumonia. Measurements of mortality, bacterial persistence in the lung, and dissemination indicated that secretion of ExoU had the greatest impact on virulence while secretion of ExoS had an intermediate effect and ExoT had a minor effect. It is of note that these results conclusively show for the first time that ExoS is a virulence factor. Infection with isogenic mutants secreting wild-type ExoS, ExoS defective in GTPase-activating protein (GAP) activity, or ExoS defective in ADP-ribosyltransferase activity demonstrated that the virulence of ExoS was largely dependent on its ADP-ribosyltransferase activity. The GAP activity of this protein had only a minor effect in vivo. The relative virulence associated with each of these type III effector proteins may have important prognostic implications for patients infected with P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557619      PMCID: PMC529154          DOI: 10.1128/IAI.72.12.6969-6977.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Identification of Pseudomonas aeruginosa genes required for epithelial cell injury.

Authors:  P J Kang; A R Hauser; G Apodaca; S M Fleiszig; J Wiener-Kronish; K Mostov; J N Engel
Journal:  Mol Microbiol       Date:  1997-06       Impact factor: 3.501

2.  Biochemical relationships between the 53-kilodalton (Exo53) and 49-kilodalton (ExoS) forms of exoenzyme S of Pseudomonas aeruginosa.

Authors:  S Liu; T L Yahr; D W Frank; J T Barbieri
Journal:  J Bacteriol       Date:  1997-03       Impact factor: 3.490

3.  Functional domains of Pseudomonas aeruginosa exoenzyme S.

Authors:  D A Knight; V Finck-Barbançon; S M Kulich; J T Barbieri
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

4.  Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Authors:  Alan R Hauser; Enesha Cobb; Maria Bodi; Dolors Mariscal; Jordi Vallés; Joanne N Engel; Jordi Rello
Journal:  Crit Care Med       Date:  2002-03       Impact factor: 7.598

5.  Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa.

Authors:  S M Fleiszig; T S Zaidi; M J Preston; M Grout; D J Evans; G B Pier
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

6.  Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway.

Authors:  T L Yahr; J Goranson; D W Frank
Journal:  Mol Microbiol       Date:  1996-12       Impact factor: 3.501

7.  Genetic relationship between the 53- and 49-kilodalton forms of exoenzyme S from Pseudomonas aeruginosa.

Authors:  T L Yahr; J T Barbieri; D W Frank
Journal:  J Bacteriol       Date:  1996-03       Impact factor: 3.490

8.  An improved system for gene replacement and xylE fusion analysis in Pseudomonas aeruginosa.

Authors:  H P Schweizer; T T Hoang
Journal:  Gene       Date:  1995-05-26       Impact factor: 3.688

9.  Identification of glutamic acid 381 as a candidate active site residue of Pseudomonas aeruginosa exoenzyme S.

Authors:  S Liu; S M Kulich; J T Barbieri
Journal:  Biochemistry       Date:  1996-02-27       Impact factor: 3.162

10.  Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury.

Authors:  I Kudoh; J P Wiener-Kronish; S Hashimoto; J F Pittet; D Frank
Journal:  Am J Physiol       Date:  1994-11
View more
  132 in total

1.  Traversal of multilayered corneal epithelia by cytotoxic Pseudomonas aeruginosa requires the phospholipase domain of exoU.

Authors:  Julio C Ramirez; Suzanne M J Fleiszig; Aaron B Sullivan; Connie Tam; Roya Borazjani; David J Evans
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-01-25       Impact factor: 4.799

2.  Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity.

Authors:  Jeff L Veesenmeyer; Heather Howell; Andrei S Halavaty; Sebastian Ahrens; Wayne F Anderson; Alan R Hauser
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

Review 3.  Innate immune responses to Pseudomonas aeruginosa infection.

Authors:  Elise G Lavoie; Tamding Wangdi; Barbara I Kazmierczak
Journal:  Microbes Infect       Date:  2011-08-02       Impact factor: 2.700

4.  Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Authors:  Daniel Aiello; John D Williams; Helena Majgier-Baranowska; Ishan Patel; Norton P Peet; Jin Huang; Stephen Lory; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

5.  The type III pseudomonal exotoxin U activates the c-Jun NH2-terminal kinase pathway and increases human epithelial interleukin-8 production.

Authors:  Alayne Cuzick; Fiona R Stirling; Susan L Lindsay; Thomas J Evans
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Structural evidence suggests that antiactivator ExsD from Pseudomonas aeruginosa is a DNA binding protein.

Authors:  Robert C Bernhards; Xing Jing; Nancy J Vogelaar; Howard Robinson; Florian D Schubot
Journal:  Protein Sci       Date:  2009-03       Impact factor: 6.725

7.  In vitro assays to monitor the activity of Pseudomonas aeruginosa Type III secreted proteins.

Authors:  Stephanie L Rolsma; Dara W Frank
Journal:  Methods Mol Biol       Date:  2014

8.  Experimental Sepsis Severity Score Associated to Mortality and Bacterial Spreading is Related to Bacterial Load and Inflammatory Profile of Different Tissues.

Authors:  Muryel Carvalho Gonçalves; Verônica Vargas Horewicz; Débora Denardin Lückemeyer; Arthur Silveira Prudente; Jamil Assreuy
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

9.  Pseudomonas aeruginosa induces localized immunosuppression during pneumonia.

Authors:  Maureen H Diaz; Ciara M Shaver; John D King; Srinidhi Musunuri; Jeffrey A Kazzaz; Alan R Hauser
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

10.  Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin.

Authors:  Reuben Ramphal; Viviane Balloy; Jeevan Jyot; Amrisha Verma; Mustapha Si-Tahar; Michel Chignard
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.